{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:10:15Z","timestamp":1767046215018},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The COVID-19 pandemic has led to a reduction in routine in-person medical care; however, it is unknown whether there have been any changes in visit rates among patients with hematologic neoplasms.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine associations between the COVID-19 pandemic and in-person visits and telemedicine use among patients undergoing active treatment for hematologic neoplasms.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Data for this retrospective observational cohort study were obtained from a nationwide electronic health record\u2013derived, deidentified database. Data for patients with hematologic neoplasms who had received at least 1 systemic line of therapy between March 1, 2016, and February 28, 2021, were included. Treatments were categorized into 3 types: oral therapy, outpatient infusions, and inpatient infusions. The data cutoff date was April 30, 2021, when study analyses were conducted.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Monthly visit rates were calculated as the number of documented visits (telemedicine or in-person) per active patient per 30-day period. We used time-series forecasting methods on prepandemic data (March 2016 to February 2020) to estimate expected rates between March 1, 2020, and February 28, 2021 (if the pandemic had not occurred).<\/jats:p><\/jats:sec>Results<\/jats:title>This study included data for 24\u202f261 patients, with a median age of 68 years (IQR, 60-75 years). A total of 6737 patients received oral therapy, 15\u202f314 received outpatient infusions, and 8316 received inpatient infusions. More than half of patients were men (14\u202f370 [58%]) and non-Hispanic White (16 309 [66%]). Early pandemic months (March to May 2020) demonstrated a significant 21% reduction (95% prediction interval [PI], 12%-27%) in in-person visit rates averaged across oral therapy and outpatient infusions. Reductions in in-person visit rates were also significant for all treatment types for multiple myeloma (oral therapy: 29% reduction; 95% PI, 21%-36%; P<\/jats:italic>\u2009=\u2009.001; outpatient infusions: 11% reduction; 95% PI, 4%-17%; P<\/jats:italic>\u2009=\u2009.002; inpatient infusions: 55% reduction; 95% PI, 27%-67%; P<\/jats:italic>\u2009=\u2009.005), for oral therapy for chronic lymphocytic leukemia (28% reduction; 95% PI, 12%-39%; P<\/jats:italic>\u2009=\u2009.003), and for outpatient infusions for mantle cell lymphoma (38% reduction; 95% PI, 6%-54%; P<\/jats:italic>\u2009=\u2009.003) and chronic lymphocytic leukemia (20% reduction; 95% PI, 6%-31%; P<\/jats:italic>\u2009=\u2009.002). Telemedicine visit rates were highest for patients receiving oral therapy, with greater use in the early pandemic months and a subsequent decrease in later months.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients with hematologic neoplasms, documented in-person visit rates for those receiving oral therapy and outpatient infusions significantly decreased during the early pandemic months but returned to close to projected rates in the later half of 2020. There were no statistically significant reductions in the overall in-person visit rate for patients receiving inpatient infusions. There was higher telemedicine use in the early pandemic months, followed by a decline, but use was persistent in the later half of 2020. Further studies are needed to ascertain associations between the COVID-19 pandemic and subsequent cancer outcomes and the evolution of telemedicine use for care delivery.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.16642","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T15:02:17Z","timestamp":1685977337000},"page":"e2316642","source":"Crossref","is-referenced-by-count":7,"title":["The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021"],"prefix":"10.1001","volume":"6","author":[{"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, University of Alabama at Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal W.","family":"Lau","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc, New York, New York"},{"name":"Now with Palantir Technologies, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Davidoff","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"Section of Hematology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of Alabama at Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Calip","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Center, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Center, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Miksad","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc, New York, New York"},{"name":"Boston Medical Center, Boston University, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi B.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Takvorian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[{"name":"Section of Hematology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlene K.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Flatiron Health, Inc, New York, New York"},{"name":"Now with BeiGene, Ridgefield Park, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"4","key":"zoi230506r1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1056\/NEJMc2014816","article-title":"Collateral effect of Covid-19 on stroke evaluation in the United States.","volume":"383","author":"Kansagra","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi230506r2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJMc2015630","article-title":"The COVID-19 pandemic and the incidence of acute myocardial infarction.","volume":"383","author":"Solomon","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi230506r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29973","article-title":"Changes in virtual and in-person health care utilization in a large health system during the COVID-19 pandemic.","volume":"4","author":"Zachrison","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi230506r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39076","article-title":"Analysis of emergency department encounters among high users of health care and social service systems before and during the COVID-19 pandemic.","volume":"5","author":"Molina","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi230506r5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jama.2021.24294","article-title":"Trends in US ambulatory care patterns during the COVID-19 pandemic, 2019-2021.","volume":"327","author":"Mafi","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"zoi230506r6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.7326\/M20-1133","article-title":"A war on two fronts: cancer care in the time of COVID-19.","volume":"172","author":"Kutikov","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi230506r7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi230506r8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-020-05828-7","article-title":"Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic.","volume":"184","author":"Papautsky","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"zoi230506r9","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.v5.1","article-title":"Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care delivery.","volume":"5","author":"Perkons","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"9","key":"zoi230506r10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/OP.20.00807","article-title":"Time to treatment initiation for breast cancer during the 2020 COVID-19 pandemic.","volume":"17","author":"Hawrot","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"zoi230506r11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/GO.20.00639","article-title":"Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review.","volume":"7","author":"Riera","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"zoi230506r12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi230506r13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v69.1","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"zoi230506r16","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.22.00118","article-title":"Assessing the contribution of scanned outside documents to the completeness of real-world data abstraction.","volume":"7","author":"Zhao","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"zoi230506r18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/hec.v28.2","article-title":"Excess influenza hospital admissions and costs due to the 2009 H1N1 pandemic in England.","volume":"28","author":"Lau","year":"2019","journal-title":"Health Econ"},{"issue":"1","key":"zoi230506r19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/irv.2009.3.issue-1","article-title":"Estimates of US influenza-associated deaths made using four different methods.","volume":"3","author":"Thompson","year":"2009","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"zoi230506r20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2307\/1392187","article-title":"Lag order and critical values of the augmented Dickey\u2013Fuller test.","volume":"13","author":"Cheung","year":"1995","journal-title":"J Bus Econ Stat"},{"issue":"1","key":"zoi230506r23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jamaoncol.2021.5784","article-title":"Evaluation of telemedicine use among US patients with newly diagnosed cancer by socioeconomic status.","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"11","key":"zoi230506r24","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.bbmt.2020.07.027","article-title":"Guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients.","volume":"26","author":"Waghmare","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"zoi230506r25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/oncolo\/oyac046","article-title":"Inequity in telemedicine use among patients with cancer in the Deep South during the COVID-19 pandemic.","volume":"27","author":"Shao","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"zoi230506r26","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1002\/onco.13676","article-title":"Rapid implementation of telemedicine during the COVID-19 pandemic: perspectives and preferences of patients with cancer.","volume":"26","author":"Hasson","year":"2021","journal-title":"Oncologist"},{"issue":"3","key":"zoi230506r27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/OP.20.00822","article-title":"Policy and health: leveraging a social determinants of health framework to alleviate the impact of the COVID-19 pandemic on patients with cancer.","volume":"17","author":"Borno","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"zoi230506r21","volume-title":"Time Series Analysis: Forecasting and Control","author":"Box","year":"2015","edition":"5th ed"},{"key":"zoi230506r14","unstructured":"Birnbaum? B, Nussbaum? N, Seidl-Rathkopf? K, . Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research.? arXiv. Preprint posted online January 13, 2020. doi:10.48550\/arXiv.2001.09765"},{"key":"zoi230506r15","doi-asserted-by":"crossref","unstructured":"Ma? X, Long? L, Moon? S, Adamson? BJS, Baxi? SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR.? medRxiv. Preprint posted online May 30, 2020. doi:10.1101\/2020.03.16.20037143?","DOI":"10.1101\/2020.03.16.20037143"},{"key":"zoi230506r17","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network website. Accessed March 31, 2023. https:\/\/www.nccn.org"},{"key":"zoi230506r22","unstructured":"American Academy of Family Physicians. Using telehealth to care for patients during the COVID-19 pandemic. Updated 2020. Accessed March 31, 2023. https:\/\/www.aafp.org\/family-physician\/patient-care\/current-hot-topics\/recent-outbreaks\/covid-19\/covid-19-telehealth.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2805573\/goyal_2023_oi_230506_1685031945.04283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T15:02:24Z","timestamp":1685977344000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2805573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.16642","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}